Xeris Pharmaceuticals Awarded a NIH/NIDDK SBIR Fast Track Grant to Advance its Glucagon Mini-Dose Pen for Treatment of Mild to Moderate Hypoglycemia
23 sept. 2013 12h15 HE
|
Xeris Pharmaceuticals, Inc.
AUSTIN, Texas, Sept. 23, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an
Austin-based, biopharmaceutical company developing patient-friendly
injectable treatments for diabetes and...
Xeris Pharmaceuticals Presents Non-Aqueous Glucagon Stability Data at the American Diabetes Association 73nd Scientific Sessions
21 juin 2013 10h00 HE
|
Xeris Pharmaceuticals, Inc.
Austin, TX, June 21, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that it is
presenting at the American Diabetes Association 73nd Scientific
Sessions in Chicago, IL...
Xeris Pharmaceuticals Awarded Phase II Funding of NIH Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas
17 avr. 2013 11h39 HE
|
Xeris Pharmaceuticals, Inc.
Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based,
pharmaceutical company developing patient-friendly injectable
treatments for diabetes and other...
Xeris Pharmaceuticals Closed 2012 with $6M In Additional Funding
11 févr. 2013 09h42 HE
|
Xeris Pharmaceuticals, Inc.
Austin, TX, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging
pharmaceutical company developing patient-friendly injectable
treatments for diabetes,...
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Bi-Hormonal Artificial Pancreas
31 juil. 2012 10h41 HE
|
Xeris Pharmaceuticals, Inc.
Austin, TX, July 31, 2012 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging
biopharmaceutical company developing patient-friendly injectable
treatments for diabetes...
Xeris Pharmaceuticals Receives U.S. Patent for Injection of Ultra-Concentrated Drugs and Biologics
20 mars 2012 11h18 HE
|
Xeris Pharmaceuticals, Inc.
Austin, TX, March 20, 2012 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that is has been granted U.S. Patent No. 8,110,209, "Intracutaneous Injection," modernizing drug...